

IN THE SPECIFICATION:

Please amend the specification, as follows:

ex. note On page 17, please replace the paragraph beginning on line 4 ¹⁴ with the following paragraph:

A In a specific embodiment, the present invention provides methods for preventing, treating or ameliorating one or more symptoms associated with a RSV infection in a mammal, said methods comprising administering to said mammal a first dose of one or more antibodies or fragments thereof comprising a VH domain having an amino acid sequence of SEQ ID NO:7, 9, 16, 23, 28, 33, 36, 40, 44, 48, 51, 56 or 74 and/or a VL domain having an amino acid sequence of SEQ ID NO:8, 12, 20, 25, 30, 34, 38, 42, 46, 52, 55, 57, 58, 60, 62, 64, 65, 75 to achieve a therapeutically or prophylactically effective serum titer, wherein said effective serum titer is less than 30 µg/ml (and is preferably at least 2 µg/ml, more preferably at least 4 µg/ml, and most preferably at least 6 µg/ml) after a certain number of days (for example, but not limited to, 20, 25, 30 or 35 days) without any other dosing within that period. In a preferred embodiment, the present invention provides methods for preventing, treating or ameliorating one or more symptoms associated with a RSV infection in a mammal, said methods comprising administering to said mammal a first dose of one or more antibodies or fragments thereof comprising a VH domain having an amino acid sequence of SEQ ID NO:16, 23, 28, 33, 36, 40, 44, 48, or 51 and/or a VL domain having an amino acid sequence of SEQ ID NO:20, 25, 30, 34, 38, 42, 46, 52, 75 or 52 to achieve a therapeutically or prophylactically effective serum titer, wherein said effective serum titer is less than 30 µg/ml (and is preferably at least 2 µg/ml, more preferably at least 4 µg/ml, and most preferably at least 6 µg/ml) after a certain number of days (for example, but not limited to, 20, 25, 30 or 35 days) without any other dosing within that period. In another embodiment, the present invention provides methods for preventing, treating or ameliorating one or more symptoms associated with a RSV infection in a mammal, said methods comprising administering to said mammal a first dose of one or more antibodies or fragments thereof comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:19 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6 to a therapeutically or prophylactically effective serum titer, wherein said effective serum titer is less than 30 µg/ml (and is preferably at least 2 µg/ml, more preferably at least 4 µg/ml, and most preferably at least 6 µg/ml) after a certain number of days (for example, but not limited to, 20, 25, 30 or 35 days) without any other dosing within that period.

On page 44, please replace the paragraph beginning on line 27 with the following paragraph:

A2 In a specific embodiment, an antibody of the present invention is SYNAGIS® or an antibody-binding fragment thereof (*e.g.*, one or more complementarity determining regions (CDRs) of SYNAGIS®). The amino acid sequence of SYNAGIS® is disclosed, *e.g.*, in Johnson et al., 1997, J. Infectious Disease 176:1215-1224, and U.S. Patent No. 5,824,307. In alternative embodiment, an antibody of the present invention or fragment thereof is not SYNAGIS® or a fragment of SYNAGIS®.

On page 45, please replace the paragraph beginning on line 26 with the following paragraph:

A3 In a specific embodiment, an antibody of the present invention comprises the amino acid sequence of SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7. Preferably, an antibody of the present invention comprises the amino acid sequence of AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7. In a preferred embodiment, an antibody of the present invention comprises a Fab fragment having the amino acid sequence of a Fab fragment having the amino acid sequence of 1X-493L2FR, H3-F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A4B4, A17d4, or A8c7.

On page 46, please replace the paragraph beginning on line 1 with the following paragraph:

A4 cont'd. In another embodiment, an antibody fragment of the present invention comprises the amino acid sequence of a portion of SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7 that immunospecifically binds to a RSV antigen. In another embodiment, an antibody fragment of the present invention comprises a portion of a

Fab fragment having the amino acid sequence of 1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, 6H8, L1-7E5, L2-15B10, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A4B4, A17d4, or A8c7.

*4
A concluded.*

On page 47, please replace the Table 2 beginning with the following Table 2:

Table 2. Antibodies & Fragments Thereof

ANTIBODY	VH Domain	VH CDR1	VH CDR2	VH CDR3	VL Domain	VL CDR1	VL CDR2	VL CDR3
**SYNAGIS®	SEQ ID NO:7	TSGMSVG (SEQ ID NO:1)	DIWWDKKDY NPSLKS (SEQ ID NO:2)	SMITNWFYFDV (SEQ ID NO:3)	SEQ ID NO:8	KCQLSVGYMH (SEQ ID NO:4)	DTSKLAS (SEQ ID NO:5)	FQSGYPFT (SEQ ID NO:6)
***AFFF	SEQ ID NO:9	TAGMSVG (SEQ ID NO:10)	DIWWDKKDYN PSLKS (SEQ ID NO:2)	SMITNWFYFDV (SEQ ID NO:11)	SEQ ID NO:12	SASSSVGYMH (SEQ ID NO:13)	DTEKLAS (SEQ ID NO:14)	FQSGYPFT (SEQ ID NO:15)
***P12F2	SEQ ID NO:16	TPGMSVG (SEQ ID NO:17)	DIWWDKKHYN PSLKD (SEQ ID NO:18)	DMIFNWFYFDV (SEQ ID NO:19)	SEQ ID NO:20	SLSSRVGYMH (SEQ ID NO:21)	DTEVLSS (SEQ ID NO:22)	FQSGYPFT (SEQ ID NO:6)
***P12F4	SEQ ID NO:23	TPGMSVG (SEQ ID NO:17)	DIWWDGKKHYN PSLKD (SEQ ID NO:24)	DMIFNWFYFDV (SEQ ID NO:19)	SEQ ID NO:25	SLSSRVGYMH (SEQ ID NO:21)	DTRGLPS (SEQ ID NO:27)	FQSGYPFT (SEQ ID NO:6)
***P11d4	SEQ ID NO:28	TPGMSVG (SEQ ID NO:17)	DIWWDGKKHYN PSLKD (SEQ ID NO:24)	DMIFNWFYFDV (SEQ ID NO:29)	SEQ ID NO:30	SFSSRVGYMH (SEQ ID NO:31)	DTMRLAS (SEQ ID NO:32)	FQSGYPFT (SEQ ID NO:6)
***Ale9	SEQ ID NO:33	TAGMSVG (SEQ ID NO:10)	DIWWDGKKHYN PSLKD (SEQ ID NO:24)	DMIFNWFYFDV (SEQ ID NO:29)	SEQ ID NO:34	SLSSRVGYMH (SEQ ID NO:21)	DTEKLSS (SEQ ID NO:35)	FQSGYPFT (SEQ ID NO:6)

*PS
concluded*

95
Conced.

***A12a6	SEQ ID NO:36	TAGMSVG (SEQ ID NO:10)	DIWWDGKKDYN PSLKD (SEQ ID NO:37)	DMIFNWFYFDV (SEQ ID NO:19)	SEQ ID NO:38	SASSRVGYMH (SEQ ID NO:39)	DTEKLSS (SEQ ID NO:35)	FQSGYPFT (SEQ ID NO:6)
***A13c4	SEQ ID NO:40	TAGMSVG (SEQ ID NO:10)	DIWWDGKKSYN PSLKD (SEQ ID NO:41)	DMIFNWFYFDV (SEQ ID NO:19)	SEQ ID NO:42	SLSSRVGYMH (SEQ ID NO:21)	DTMYQSS (SEQ ID NO:43)	FQSGYPFT (SEQ ID NO:6)
***A17d4	SEQ ID NO:44	TAGMSVG (SEQ ID NO:10)	DIWWDGKKSYN PSLKD (SEQ ID NO:45)	DMIFNWFYFDV (SEQ ID NO:19)	SEQ ID NO:46	LPSSRVGYMH (SEQ ID NO:47)	DTMYQSS (SEQ ID NO:43)	FQSGYPFT (SEQ ID NO:6)
***A4B4	SEQ ID NO:48	TAGMSVG (SEQ ID NO:10)	DIWWDGKKHYN PSLKD (SEQ ID NO:18)	DMIFNWFYFDV (SEQ ID NO:19)	SEQ ID NO:75	SASSRVGYMH (SEQ ID NO:73)	DTLLIDS (SEQ ID NO:50)	FQSGYPFT (SEQ ID NO:6)
***A8c7	SEQ ID NO:51	TAGMSVG (SEQ ID NO:10)	DIWWDGKKSYN PSLKD (SEQ ID NO:45)	DMIFNWFYFDV (SEQ ID NO:29)	SEQ ID NO:52	SPSSRVGYMH (SEQ ID NO:53)	DTRYQSS (SEQ ID NO:54)	FQSGYPFT (SEQ ID NO:6)
*1X-493L2FR	SEQ ID NO:7	TSGMSVG (SEQ ID NO:1)	DIWWDGKKDYN PSLKS (SEQ ID NO:2)	SMITNWFYFDV (SEQ ID NO:3)	SEQ ID NO:55	SASSSVGYMH (SEQ ID NO:13)	DTSKLAS (SEQ ID NO:5)	FQSGYPFT (SEQ ID NO:6)
*H3-3F4	SEQ ID NO:56	TAGMSVG (SEQ ID NO:10)	DIWWDGKKDYN PSLKS (SEQ ID NO:2)	DMIFNWFYFDV (SEQ ID NO:29)	SEQ ID NO:57	SASSSVGYMH (SEQ ID NO:13)	DTEKLAS (SEQ ID NO:14)	FQSGYPFT (SEQ ID NO:6)
*M3H9	SEQ ID NO:56	TAGMSVG (SEQ ID NO:10)	DIWWDGKKDYN PSLKS (SEQ ID NO:2)	DMIFNWFYFDV (SEQ ID NO:29)	SEQ ID NO:58	SASSSVGYMH (SEQ ID NO:13)	DTYKQTS (SEQ ID NO:59)	FQSGYPFT (SEQ ID NO:6)

95
contd.

*Y10H6	SEQ ID NO:56	TAGMSVG (SEQ ID NO:10)	DIWWDKKDYN PSLKS (SEQ ID NO:2)	<u>DMITN</u> WYFDV (SEQ ID NO:29)	SEQ ID NO:60	<u>SA</u> SSSVGYMH (SEQ ID NO:13)	D <u>TR</u> YLSS (SEQ ID NO:61)	FQSGYPFT (SEQ ID NO:6)
*DG	SEQ ID NO:74	TAGMSVG (SEQ ID NO:10)	DIWWDKKDYN PSLKS (SEQ ID NO:2)	<u>DMITN</u> WYFDV (SEQ ID NO:29)	SEQ ID NO:57	<u>SA</u> SSSVGYMH (SEQ ID NO:13)	D <u>T</u> EKLAS (SEQ ID NO:14)	FQSGYPFT (SEQ ID NO:6)
*6H8	SEQ ID NO:74	TAGMSVG (SEQ ID NO:10)	DIWWDKKDYN PSLKS (SEQ ID NO:2)	<u>DMITN</u> WYFDV (SEQ ID NO:29)	SEQ ID NO:62	<u>SA</u> SSSVGYMH (SEQ ID NO:13)	D <u>T</u> EKL <u>T</u> S (SEQ ID NO:63)	FQSGYPFT (SEQ ID NO:6)
*L1-7E5	SEQ ID NO:74	TAGMSVG (SEQ ID NO:10)	DIWWDKKDYN PSLKS (SEQ ID NO:2)	<u>DMITN</u> WYFDV (SEQ ID NO:29)	SEQ ID NO:64	<u>SA</u> SSSVGYMH (SEQ ID NO:39)	D <u>T</u> EKLAS (SEQ ID NO:14)	FQSGYPFT (SEQ ID NO:6)
*L2-15B10	SEQ ID NO:74	TAGMSVG (SEQ ID NO:10)	DIWWDKKDYN PSLKS (SEQ ID NO:2)	<u>DMITN</u> WYFDV (SEQ ID NO:26)	SEQ ID NO:65	<u>SA</u> SSSVGYMH (SEQ ID NO:13)	D <u>T</u> EKLAS (SEQ ID NO:66)	FQSGYPFT (SEQ ID NO:6)
*A13a11	SEQ ID NO:67	TAGMSVG (SEQ ID NO:10)	DIWWDKKHYN PSLKD (SEQ ID NO:18)	<u>DMITN</u> WYFDV (SEQ ID NO:29)	SEQ ID NO:68	<u>SP</u> SSSVGYMH (SEQ ID NO:31)	D <u>T</u> YRHSS (SEQ ID NO:69)	FQSGYPFT (SEQ ID NO:6)
*A1h5	SEQ ID NO:33	TAGMSVG (SEQ ID NO:10)	DIWWDGKKHYN PSLKD (SEQ ID NO:24)	<u>DMITN</u> WYFDV (SEQ ID NO:29)	SEQ ID NO:70	<u>SL</u> SSSVGYMH (SEQ ID NO:71)	D <u>T</u> FFHRS (SEQ ID NO:72)	FQSGYPFT (SEQ ID NO:6)

Bold faced & underlined amino acid residues are the residues which differ from the amino acid residues in SYNAGIS®; Fab fragment (*);
Monoclonal antibody (**); Monoclonal Antibody & Fab fragment (***)

96
Cont'd.

On page 51, please replace the Table 3 beginning with the following Table3:

Table 3. CDR Sequences

VH CDR1	VH CDR2	VH CDR3	VL CDR1	VL CDR2	VL CDR3
TSGMSVG (SEQ ID NO:1)	DIWWD DKK DYNPSLK S (SEQ ID NO:2)	S MITN W YFDV (SEQ ID NO:3)	KCOLSVGYMH (SEQ ID NO:4)	DTSKLAS (SEQ ID NO:5)	FQSGYPFT (SEQ ID NO:6)
TPGMSVG (SEQ ID NO:17)	DIWWD DKK HHYNPSLK D (SEQ ID NO:18)	D MITN F YFDV (SEQ ID NO:76)	KCOSSVGYMH (SEQ ID NO:77)	DTSYLAS (SEQ ID NO:78)	
TAGMSVG (SEQ ID NO:10)	DIWWD DKK HHYNPSLK S (SEQ ID NO:79)	D MITN W YFDV (SEQ ID NO:80)	KCOSRVGYMH (SEQ ID NO:81)	DTSYLSS (SEQ ID NO:82)	
	DIWWD DKK DYNPSLK D (SEQ ID NO:83)	D MIFN W YFDV (SEQ ID NO:29)	KCOLRVGYMH (SEQ ID NO:84)	DTKKLSS (SEQ ID NO:85)	
	DIWWD DKK HHYNPSLK D (SEQ ID NO:18)	D MIFN F YFDV (SEQ ID NO:19)	KLQLSVGYMH (SEQ ID NO:86)	DTFYLSS (SEQ ID NO:49)	
	DIWWD DKK HHYNPSLK S (SEQ ID NO:87)	S MITN F YFDV (SEQ ID NO:11)	KLOSSVGYMH (SEQ ID NO:88)	DTFKLAS (SEQ ID NO:14)	
	DIWWD DKK DYNPSLK D (SEQ ID NO:89)	S MIFN W YFDV (SEQ ID NO:90)	KLOSrvGYMH (SEQ ID NO:91)	DTFKLSS (SEQ ID NO:35)	
	DIWWDG KK HHYNPSLK D (SEQ ID NO:24)	S MIFN F YFDV (SEQ ID NO:92)	KLQLRVGYMH (SEQ ID NO:93)	DTFYLAS (SEQ ID NO:94)	
	DIWWDG KK DYNPSLK S (SEQ ID NO:95)		KLSLSVGYMH (SEQ ID NO:96)	DTSKLPS (SEQ ID NO:97)	

96
contd.

	DIWWDGKKDYNPSLKD (SEQ ID NO:37)		KLSSSVGYMH (SEQ ID NO:98)	DTSGLAS (SEQ ID NO:99)	
	DIWWDGKKHHYNPSLKŠ		KLSSRVGYMH (SEQ ID NO:101)	DTSGLPS (SEQ ID NO:102)	
	DIWWDĐKKŠYNPSLKŠ		KLRLRVGYMH (SEQ ID NO:104)	DTRGLPS (SEQ ID NO:107)	
	DIWWDĐKKŠYNPSLKĐ		KCSLSVGYMH (SEQ ID NO:106)	DTRKLAS (SEQ ID NO:107)	
	DIWWDGKKŠYNPSLKŠ		KCSSSVGYMH (SEQ ID NO:109)	DTRGLAS (SEQ ID NO:110)	
	DIWWDGKKŠYNPSLKĐ		KCSSRVGYMH (SEQ ID NO:111)	DTRKLPS (SEQ ID NO:112)	
			KCSLRVGYMH (SEQ ID NO:113)	DTMRLAS (SEQ ID NO:32)	
			SLSLSVGYMH (SEQ ID NO:114)	DTMKLAS (SEQ ID NO:115)	
			SLSSSVGYMH (SEQ ID NO:116)	DTSRLAS (SEQ ID NO:117)	
			SLSSRVGYMH (SEQ ID NO:21)	DTSLLAS (SEQ ID NO:118)	
			SLSLRVGYMH (SEQ ID NO:119)	DTSLDŠS (SEQ ID NO:120)	
			SCOLSVGYMH (SEQ ID NO:121)	DTSKLDŠS (SEQ ID NO:122)	

Ab
cont.

			<u>SCOSSVGYMH</u> (SEQ ID NO:123)	<u>DTLLDS</u> (SEQ ID NO:124)	
			<u>SCOSRVGYMH</u> (SEQ ID NO:125)	<u>DTLKLDS</u> (SEQ ID NO:126)	
			<u>SCQLRVGYMH</u> (SEQ ID NO:127)	<u>DTLLAS</u> (SEQ ID NO:128)	
			<u>SLQLSVGYMH</u> (SEQ ID NO:129)	<u>DTLKLAS</u> (SEQ ID NO:130)	
			<u>SLOSSVGYMH</u> (SEQ ID NO:131)	<u>DTSKLSS</u> (SEQ ID NO:132)	
			<u>SLOS RVGYMH</u> (SEQ ID NO:133)	<u>DTSKOAS</u> (SEQ ID NO:134)	
			<u>SLQLRVGYMH</u> (SEQ ID NO:135)	<u>DTSKOSS</u> (SEQ ID NO:136)	
			<u>SCSLSVGYMH</u> (SEQ ID NO:137)	<u>DTSYLAS</u> (SEQ ID NO:138)	
			<u>SCSSSVGYMH</u> (SEQ ID NO:139)	<u>DTSYLSS</u> (SEQ ID NO:140)	
			<u>SCSSRVGYMH</u> (SEQ ID NO:141)	<u>DTSYOAS</u> (SEQ ID NO:142)	
			<u>SCSLRVGYMH</u> (SEQ ID NO:143)	<u>DTSYOSS</u> (SEQ ID NO:144)	
			<u>KPSSRVGYMH</u> (SEQ ID NO:145)	<u>DTMYOAS</u> (SEQ ID NO:146)	

26
contd.

			<u>KPSLRVGYMH</u> (SEQ ID NO:147)	<u>DTMYOSS</u> (SEQ ID NO:43)	
			<u>KPSSSVGYMH</u> (SEQ ID NO:148)	<u>DTMKOAS</u> (SEQ ID NO:149)	
			<u>KPSLSVGYMH</u> (SEQ ID NO:150)	<u>DTMKOSS</u> (SEQ ID NO:151)	
			<u>KPOSRRVGYMH</u> (SEQ ID NO:152)	<u>DTMYLAS</u> (SEQ ID NO:153)	
			<u>KPOLRVGYMH</u> (SEQ ID NO:154)	<u>DTMYLSS</u> (SEQ ID NO:155)	
			<u>KPOSSVGYMH</u> (SEQ ID NO:156)	<u>DTMKLAS</u> (SEQ ID NO:157)	
			<u>KPOLSVGYMH</u> (SEQ ID NO:158)	<u>DTMKLSS</u> (SEQ ID NO:159)	
			<u>SPSSRVGYMH</u> (SEQ ID NO:160)	<u>DTSKLSS</u> (SEQ ID NO:161)	
			<u>SPSLRVGYMH</u> (SEQ ID NO:162)	<u>DTRYOAS</u> (SEQ ID NO:163)	
			<u>SPSSSVGYMH</u> (SEQ ID NO:164)	<u>DTRYOSS</u> (SEQ ID NO:54)	
			<u>SPSLSVGYMH</u> (SEQ ID NO:165)	<u>DTRKOAS</u> (SEQ ID NO:166)	
			<u>SPOSRRVGYMH</u> (SEQ ID NO:167)	<u>DTRKOSS</u> (SEQ ID NO:168)	

96
cont'd

			<u>SPOLRVGYMH</u> (SEQ ID NO:169)	<u>DTRK</u> <u>KLAS</u> (SEQ ID NO:170)	
			<u>SPOSSVGYMH</u> (SEQ ID NO:171)	<u>DTRK</u> <u>LSS</u> (SEQ ID NO:172)	
			<u>SPOLSVGYMH</u> (SEQ ID NO:173)	<u>DTRY</u> <u>LAS</u> (SEQ ID NO:174)	
			<u>KAOSRVGYMH</u> (SEQ ID NO:175)	<u>DTRY</u> <u>LSS</u> (SEQ ID NO:177)	
			<u>KAOLRVGYMH</u> (SEQ ID NO:176)		
			<u>KAOSSVGYMH</u> (SEQ ID NO:178)		
			<u>KAOLSVGYMH</u> (SEQ ID NO:179)		
			<u>KASSRVGYMH</u> (SEQ ID NO:180)		
			<u>KASLRVGYMH</u> (SEQ ID NO:181)		
			<u>KASSSVGYMH</u> (SEQ ID NO:182)		
			<u>KASLSVGYMH</u> (SEQ ID NO:183)		
			<u>SASSRVGYMH</u> (SEQ ID NO:39)		

96
cont'd.

			<u>SASLRVGYMH</u> (SEQ ID NO:184)			
			<u>SASSSVGYMH</u> (SEQ ID NO:13)			
			<u>SASLSVGYMH</u> (SEQ ID NO:185)			
			<u>SAQSRVGYMH</u> (SEQ ID NO:186)			
			<u>SAQLRVGYMH</u> (SEQ ID NO:187)			
			<u>SAOSSVGYMH</u> (SEQ ID NO:188)			
			<u>LPSSRVGYMH</u> (SEQ ID NO:47)			
			<u>LPSLSVGYMH</u> (SEQ ID NO:189)			
			<u>LPSSSVGYMH</u> (SEQ ID NO:190)			
			<u>LPSLRVGYMH</u> (SEQ ID NO:191)			
			<u>LCSSRVGYMH</u> (SEQ ID NO:192)			
			<u>LCSLSVGYMH</u> (SEQ ID NO:193)			

96
cont'd

			<u>LCSSSVGYMH</u> (SEQ ID NO:194)			
			<u>LCSLRVGYMH</u> (SEQ ID NO:195)			
			<u>LPQSRVGYMH</u> (SEQ ID NO:196)			
			<u>LPOLSVGYMH</u> (SEQ ID NO:197)			
			<u>LPOSSVGYMH</u> (SEQ ID NO:198)			
			<u>LPQLRVGYMH</u> (SEQ ID NO:199)			
			<u>LCQSRVGYMH</u> (SEQ ID NO:200)			
			<u>LCOLSVGYMH</u> (SEQ ID NO:201)			
			<u>LCQSSVGYMH</u> (SEQ ID NO:202)			
			<u>LCOLRVGYMH</u> (SEQ ID NO:203)			
			<u>SAQLSVGYMH</u> (SEQ ID NO:204)			

On page 58, please replace the paragraph beginning on line 1 with the following paragraph:

97 In one embodiment of the present invention, antibodies or fragments thereof comprise a VH CDR1 having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:10 or SEQ ID NO:17. In another embodiment, antibodies or fragments thereof comprise a VH CDR2 having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45. In another embodiment, antibodies comprise a VH CDR3 having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29. In a preferred embodiment, antibodies or fragments thereof comprise a VH CDR1 having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:10 or SEQ ID NO:17, a VH CDR2 having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45, and a VH CDR3 having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29.

On page 58, please replace the paragraph beginning on line 20 with the following paragraph:

98 In one embodiment of the present invention, antibodies or fragments thereof comprise a VL CDR1 having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73. In another embodiment, antibodies or fragments thereof comprise a VL CDR2 having the amino acid sequence of SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72. In another embodiment, antibodies or fragments thereof comprise a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:15. In a preferred embodiment, antibodies or fragments thereof comprise a VL CDR1 having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73, a VL CDR2 having the amino acid sequence of SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72, and a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:15.

On page 59, please replace the paragraph beginning on line 1 with the following paragraph:

a⁹ The present invention also provides antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, said antibodies or antibody fragments comprising a VH domain disclosed herein combined with a VL domain disclosed herein, or other VL domain. The present invention further provides antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, said antibodies or fragments comprising a VL domain disclosed herein combined with a VH domain disclosed herein, or other VH domain. In a preferred embodiment, antibodies or fragments thereof that immunospecifically bind to a RSV antigen comprise a VH domain having the amino acid sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:16, SEQ ID NO:23, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:56, SEQ ID NO:67 or SEQ ID NO:74 and a VL domain having the amino acid sequence of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:68, SEQ ID NO:70 or SEQ ID NO:75.

On page 59, please replace the paragraph beginning on line 16 with the following paragraph:

a¹⁰ The present invention also provides antibodies or fragments thereof comprising one or more VH CDRs and one or more VL CDRs listed in Table 2 and/or Table 3. In particular, the invention provides for an antibody or fragment thereof comprising a VH CDR1 and a VL CDR1, a VH CDR1 and a VL CDR2, a VH CDR1 and a VL CDR3, a VH CDR2 and a VL CDR1, VH CDR2 and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDR1, a VH CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination thereof of the VH CDRs and VL CDRs listed in Table 2. The invention also provides for an antibody or fragment thereof comprising a VH CDR1 and a VL CDR1, a VH CDR1 and a VL CDR2, a VH CDR1 and a VL CDR3, a VH CDR2 and a VL CDR1, VH CDR2 and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDR1, a VH CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination thereof of the VH CDRs and VL CDRs listed in Table 3. The invention also provides for an antibody or fragment thereof comprising a VH CDR1 and a VL CDR1, a VH CDR1 and a VL CDR2,

a10
a VH CDR1 and a VL CDR3, a VH CDR2 and a VL CDR1, VH CDR2 and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDR1, a VH CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination thereof of the VH CDRs and VL CDRs listed in Table 2 and Table 3.

On page 59, please replace the paragraph beginning on line 33 with the following paragraph:

a11
In one embodiment, an antibody or fragment thereof comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:10 or SEQ ID NO:17 and a VL CDR1 having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:10 or SEQ ID NO:17 and a VL CDR2 having the amino acid sequence of SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:10 or SEQ ID NO:17 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:15.

On page 60, please replace the paragraph beginning on line 9 with the following paragraph:

a12
In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45 and a VL CDR1 having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45 and a VL CDR2 having the amino acid sequence of SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59,

Q12
concl'd

SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:15.

On page 60, please replace the paragraph beginning on line 24 with the following paragraph:

Q13

In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29 and a VL CDR1 having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29 and a VL CDR2 having the amino acid sequence of SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72. In a preferred embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:15.

On page 61, please replace the paragraph beginning on line 3 with the following paragraph:

Q14

The present invention also provides for a nucleic acid molecule, generally isolated, encoding an antibody of the invention or fragment thereof. In a specific embodiment, an isolated nucleic acid molecule of the invention encodes an antibody having the amino acid sequence of SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, A8c7. Preferably, an isolated nucleic acid molecule of the invention encodes an antibody having the amino acid sequence of AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7. In another embodiment, an isolated nucleic acid

a14
molecule of the invention encodes an antibody comprising a Fab fragment having the amino acid sequence of 1X-L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7.

On page 61, please replace the paragraph beginning on line 17 with the following paragraph:

a15
In another embodiment, an isolated nucleic acid molecule of the invention encodes an antibody fragment having the amino acid sequence of portion of SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7 that immunospecifically binds to a RSV antigen. In another embodiment, an isolated nucleic acid molecule of the invention encodes an antibody fragment having the amino acid sequence of 1X-L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7.

On page 62, please replace the paragraph beginning on line 28 with the following paragraph:

a16
The present invention also provides antibodies or fragments thereof comprising derivatives of the VH domains, VH CDRs, VL domains, and VL CDRs described herein that immunospecifically bind to an RSV antigen. The present invention also provides antibodies or fragments thereof comprising derivatives of SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7. The present invention further provides antibodies or fragments thereof comprising derivatives of Fab fragments having the amino acid sequence of 1X-L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7. Standard techniques known to those of skill in the art can be used to introduce mutations in the nucleotide sequence encoding a molecule of the invention, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis which results in amino acid substitutions. Preferably, the derivatives include less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the original molecule. In a preferred embodiment, the derivatives have conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A

916
concl'd.

"conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues having side chains with similar charges have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed and the activity of the protein can be determined.

On page 63, please replace the paragraph beginning on line 25 with the following paragraph:

917

In a specific embodiment, an antibody or fragment thereof that immunospecifically binds to a RSV antigen comprises a nucleotide sequence that hybridizes to the nucleotide sequence encoding SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale109, A12a6, A13a11, A13c4, A17d4, A4B4, A8c7, 1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, 6H8, L1-7E5 or L1-15B10, under stringent conditions, e.g., hybridization to filter-bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45 °C followed by one or more washes in 0.2xSSC/0.1% SDS at about 50-65 °C, under highly stringent conditions, e.g., hybridization to filter-bound nucleic acid in 6xSSC at about 45 °C followed by one or more washes in 0.1xSSC/0.2% SDS at about 68 °C, or under other stringent hybridization conditions which are known to those of skill in the art (see, for example, Ausubel, F.M. et al., eds. , 1989, *Current Protocols in Molecular Biology*, Vol. I, Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York at pages 6.3.1-6.3.6 and 2.10.3).

On page 64, please replace the paragraph beginning on line 5 with the following paragraph:

918

In another embodiment, an antibody or fragment thereof that immunospecifically binds to a RSV antigen comprises an amino acid sequence that is at least 35%, at least 40%,

a18
concl'd.

at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale109, A12a6, A13a11, A13c4, A17d4, A4B4, A8c7, 1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, 6H8, L1-7E5 or L1-15B10.

On page 68, please replace the paragraph beginning on line 3 with the following paragraph:

a19

The present invention further provides for compositions comprising one or more antibodies of the invention or fragments thereof. In a specific embodiment, a composition of the present invention comprises one or more antibodies having an amino acid sequence of SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7. In another embodiment, a composition of the present invention comprises one or more antibodies or fragments thereof comprising a Fab fragment having an amino acid sequence of 1X-L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7.

On page 71, please replace the paragraph beginning on line 4 with the following paragraph:

a20

In one embodiment, a fusion protein of the invention comprises an antibody having the amino acid sequence of SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7 and a heterologous polypeptide. In another embodiment, a fusion protein of the invention comprises an antibody or antibody fragment having the amino acid sequence of 1X-L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7 and a heterologous polypeptide. In another embodiment, a fusion protein of the invention comprises one or more VH domains having the amino acid sequence of any one of the VH domains listed in Table 2 or one or more VL domains having the amino acid sequence of any one of the VL domains listed in Table 2 and a heterologous polypeptide. In another embodiment, a fusion protein of the present invention comprises one or more VH CDRs having the amino acid sequence of any one of the VH CDRs listed in Table 2 or Table 3 and a heterologous polypeptide. In another embodiment, a fusion protein comprises one or more VL CDRs having the amino acid sequence of any one of the VL CDRs listed in Table 2 or

Table 3 and a heterologous polypeptide. In another embodiment, a fusion protein of the invention comprises at least one VH domain and at least one VL domain listed in Table 2 and a heterologous polypeptide. In yet another embodiment, a fusion protein of the invention comprises at least one VH CDR and at least one VL CDR domain listed in Table 2 or Table 3 and a heterologous polypeptide.

A²⁰ concid.

On page 77, please replace the paragraph beginning on line 22 with the following paragraph:

In another embodiment, a mammal, preferably a human, is administered a first dose of a therapeutic or pharmaceutical composition comprising less than 15 mg/kg, preferably less than 10 mg/kg, less than 5 mg/kg, less than 3 mg/kg, less than 1 mg/kg or less than 0.5 mg/kg of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens with higher affinity and/or higher avidity than previously known antibodies (e.g., SYNAGIS®) for the prevention, treatment or amelioration of one or more symptoms associated with a RSV infection in an amount effective to induce a serum titer of at least 1 µg/ml, preferably at least 2 µg/ml, at least 5 µg/ml, at least 10 µg/ml, at least 15 µg/ml, at least 20 µg/ml, or at least 25 µg/ml 20 days (preferably 25, 30, 35, 40 days) after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the serum titer of said antibodies or antibody fragments is less than 30 µg/ml 30 days after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, said antibodies have the amino acid sequence of AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7.

A²¹

On page 78, please replace the paragraph beginning on line 1 with the following paragraph:

In another embodiment, a mammal, preferably a human, is administered a first dose of a therapeutic or pharmaceutical composition comprising less than 15 mg/kg, preferably less than 5 mg/kg, less than 3 mg/kg, less than 1 mg/kg or less than 0.5 mg/kg of one or more antibodies or fragments thereof which have increased *in vivo* half-lives and which immunospecifically bind to one or more RSV antigens with higher affinity and/or higher avidity than previously known antibodies (e.g., SYNAGIS®) for the prevention, treatment or amelioration of one or more symptoms associated with a RSV infection in an amount effective to induce a serum titer of at least 1 µg/ml, preferably at least 2 µg/ml, at least 5

A²²

*A22
cancel*
μg/ml, at least 10 μg/ml, at least 15 μg/ml, at least 20 μg/ml, or at least 25 μg/ml 25 days (preferably 30, 35, or 40 days) after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the serum titer of said antibodies or antibody fragments is less than 30 μg/ml 30 days after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the novel antibodies have the amino acid sequence of AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7.

On page 79, please replace the paragraph beginning on line 3 with the following paragraph:

A23
In one embodiment, a mammal, preferably a human, is administered a first dose of a therapeutic or pharmaceutical composition for pulmonary delivery comprising less than 15 mg/kg, preferably less than 5 mg/kg, less than 3 mg/kg, less than 1 mg/kg or less than 0.5 mg/kg, or less than 0.01 mg/kg of one or more antibodies or fragments thereof which immunospecifically bind to one or more RSV antigens with higher affinity and/or higher avidity than previously known antibodies (*e.g.*, SYNAGIS®) for the prevention, treatment or amelioration of one or more symptoms associated with a RSV infection in an amount effective to induce a titer of 20 ng per mg of lung protein (preferably at least 40 ng/mg, at least 60 ng/mg, at least 80 ng/mg, at least 50 ng/mg, at least 75 ng/mg, at least 100 ng/mg, or at least 150 ng/mg) in an intubation sample or lavage from the lungs of said mammal 20 days (preferably 25, 30, 35, or 40 days) after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the serum titer of said antibodies or antibody fragments is less than 100 ng/ml of protein 30 days after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the novel antibodies have the amino acid sequence of AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7.

On page 80, please replace the paragraph beginning on line 16 with the following paragraph:

*A24
cancel*
In one embodiment, a mammal, preferably a human, is administered a first dose of a sustained release formulation comprising less than 15 mg/kg, preferably less than 5 mg/kg, less than 3 mg/kg, less than 1 mg/kg or less than 0.5 mg/kg of one or more antibodies or fragments thereof which immunospecifically bind to one or more RSV antigens with higher

affinity and/or higher avidity than previously known antibodies (e.g., SYNAGIS®) for the prevention, treatment or amelioration of one or more symptoms associated with a RSV infection in an amount effective to induce a serum titer of at least 1 µg/ml, preferably at least 2 µg/ml, at least 5 µg/ml, at least 10 µg/ml, at least 15 µg/ml, at least 20 µg/ml, or at least 25 µg/ml for at least 10 days (preferably at least 15, at least 20, at least 25, at least 30, at least 35, or at least 40 days) after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the serum titer of said antibodies or antibody fragments is less than 30 µg/ml 30 days after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the novel antibodies have the amino acid sequence of AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7.

A24
concl'd.

On page 116, please replace Table 4 with the following Table 4:

Table 4. Summary of Kinetic Constants for High Potency Antibodies.

SEQ ID NO.	$K_{on} \times 10^5 (M^{-1}s^{-1})$	$K_{off} \times 10^{-4} (s^{-1})$	$EC_{50} (nM)$
**SYNAGIS®	2.04; 1.89; 2.18	7.64; 7.38; 7.02	3.57
**AFFF	1.08; 0.96; 1.24	2.74; 2.66; 2.06	
*1X-493L2FR	1.85	6.5	
*H3-3F4	4.59; 4.67; 5.72; 6.25; 5.33	4.45; 4.02	
*M3H9	6.05	3.38	
*Y10H6	7.57	4.62	
*DG	2.65; 2.83; 4.16; 3.18; 2.88	1.67; 4.44	
*AFFF	2.12; 1.56; 1.86	2.45; 4.46; 2.68	
*6H8	3.14; 4.44	1.78; 4.73	
*L1-7E5	3.29; 3.57; 4.05; 3.35; 4.26	1.92; 3.31; 2.29	

A25

*925
concl'd*

*L2-15B10	3.69; 2.82; 3.12; 5.33; 3.78	1.34; 4.16; 2.70	
*P12F2	6.63	2.82	0.65
*P12F4	5.27	2.99	0.70
*P11d4	5.70; 5.72	7.17	>20
*Ale9	7.9	4.53	2.5
*A12a6	7.43	2.30	0.62
*A13a11	7.35	2.50	2.04
*A13c4	7.81; 7.35	2.80	0.52

Monoclonal Antibody (**); Fab fragment (*)

On page 117, please replace Table 5 with the following Table 5:

Table 5.

Monoclonal Antibodies vs Bac-F (1:1)

926

	<u>Kon (x E+5)</u>	<u>Koff (x E-5)</u>	<u>KD (nM)</u>	<u>Chi2</u>
P12F2	4.07	12.8	0.31 (13)	0.9
P12F4	4.95	5.55	0.11 (35)	0.6
A13c4	3.00	3.96	0.13 (30)	1.2
A12a6	4.60	1.65	0.04 (98)	1.2
A1e9	4.33	14.3	0.33 (12)	2.5
A8c7	4.17	8.75	0.21 (19)	1.8
P11d4	4.66	28.9	0.62 (6)	1.0
A17d4	4.56	4.07	0.09 (43)	0.5
A4B4	4.34	1.06	0.02 (195)	1.5
SYNAGIS®	1.32	51.5	3.90 (1)	0.6

On page 118, please replace Table 6 with the following Table 6:

Table 6.

Monoclonal Antibodies vs NUF4 (1:1)

	<u>Kon (x E+5)</u>	<u>Koff (x E-5)</u>	<u>KD (nM)</u>	<u>Chi2</u>
P12F2	5.41	17.8	0.33 (26)	1.2
P12F4	9.43	22.9	0.24 (36)	0.9
A13c4	3.65	27.2	0.75 (12)	1.8
A12a6	4.00	29.1	0.73 (12)	1.9
A1e9	8.43	58.4	0.69 (13)	0.9
A8c7	8.25	53.5	0.65 (13)	0.7
P11d4	9.04	76.6	0.85 (10)	2.5
A17d4	4.99	36.2	0.73 (12)	2.0
A4B4	4.96	28.2	0.57 (15)	1.9
SYNAGIS®	3.04	265	8.70 (1)	0.4

On page 118, please replace Table 7 with the following Table 7:

Table 7.

Monoclonal Antibodies vs NUF4 (2:1)

	<u>Kon (x E+5)</u>	<u>Koff (x E-5)</u>	<u>KD (nM)</u>	<u>Chi2</u>
P12F2	2.82	23.6	0.84 (371)	1.5
P12F4	2.73	63.6	2.33 (134)	4.9
A13c4	3.20	22.5	0.70 (446)	1.7
A12a6	2.18	40.8	1.87 (167)	1.9
A1e9	3.29	139	4.22 (74)	2.8
A8c7	4.30	114	2.65 (118)	2.0
P11d4	3.66	313	8.55 (36)	3.6
A17d4	2.64	29.2	1.11 (281)	1.7

928

A4B4	2.03	40.06	2.00 (156)	1.4
SYNAGIS®	0.78	2420	312 (1)	1.3

On page 118, please replace the paragraph beginning on line 35 with the following paragraph:

929

1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, *AFFF, 6H8, L1-7E5, L2-15B10, *P12F2, *P12F4, *P11d4, *Ale9, *A12a6, *A13a11, and *A13c4 are Fab fragments having the framework sequences of Figure 1 and the indicated CDR sequences indicated listed in Table 2. SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 and A8c7 are actual monoclonal antibodies with the framework sequences of Figure 1 and constant regions as described in Johnson et al. (1997, Journal of Infectious Diseases 176:1215-1224) and U.S. Patent No. 5,824,307. The framework sequences of these antibodies may differ slightly from those of the Fab fragments.

On page 120, please replace Table 8 with the following Table 8:

Table 8. End Point RSV Microneutralization Titer Of High On Rate Mutant IgG and Fab

930

Molecule	Mean IC50 (Curve) µg/ml	STDEV Curve IC50	Fold Difference (Curve ICX50)	Mean IC50 (Control) µg/ml	STDEV Control IC50	Fold Difference (Control IC50)	n (assay repeat)
SYNAGIS ®	0.4527	0.208	-	0.5351	0.238	-	8
**Ale9	0.0625	0.0268	7	0.0645	0.0223	8	3
**A17d4	0.0342	0.022	13	0.0354	0.0187	15	4
**P11d4	0.0217	0.0331	21	0.0289	0.0110	19	5
**P12F2	0.0231	0.0141	20	0.0223	0.0083	24	6
**A8c7	0.0337	0.0309	13	0.0383	0.0283	14	5
**A12a6	0.0357	0.0316	13	0.0354	0.0261	15	7
**P12F4	0.0242	0.0163	19	0.0235	0.0076	23	7
**A13c4	0.0376	0.0268	12	0.0375	0.0213	14	6

**A4B4	0.0171	0.0018	27	0.0154	0.0041 7	35	2
*A1e9	0.157	-	3	0.125	-	4	1
*A17d4	0.0179	-	25	0.0171	-	31	1
*P11d4	>1.00	-	-	>1.00	-	-	1
*P12F2	0.0407	0.0112	11	0.0326	0.0090 5	16	2
*A8c7	0.177	-	3	0.157	-	34	1
*A12a6	0.0287	0.0041 7	16	0.0310	0.0098 2	17	2
*P12F4	0.0464	0.0079 1	10	0.0351	0.0126	15	2
*A13c4	0.0264	0.0014 1	17	0.0258	0.0007 1	21	2
*A4B4	0.0414	-	11	0.0411	-	13	1
*A13a11	0.120	0.0222	4	0.1022	0.0260	5	2
*A1h5	0.194	0.462	2	0.176	0.0625	3	2

** Monoclonal Antibody

* Fab Fragment

On page 122, please replace the paragraph beginning on line 11 with the following paragraph:

Antibodies having the amino acid sequence of A13c4, A17d4, A4B4, and SYNAGIS® were diluted in dialysate and the concentrations were determined by UV spectroscopic absorption measurements with a Perkin-Elmer Lambda 4B Spectrophotometer using an extinction coefficient of 217,000 M⁻¹ cm⁻¹ at the peak maximum at 280 nm. The diluted NUF4 concentrations were calculated from the ratio of the mass of the original sample to that of the diluted sample since its extinction coefficient was too low to determine an accurate concentration without employing and losing a large amount of sample.

After the Abstract of the Disclosure, please insert the Sequence Listing as independently numbered page 1/